Free Trial
NYSE:BAX

Baxter International (BAX) Stock Price, News & Analysis

$33.84
-0.06 (-0.18%)
(As of 03:58 PM ET)
Today's Range
$33.52
$34.09
50-Day Range
$33.90
$43.55
52-Week Range
$31.01
$50.21
Volume
2.67 million shs
Average Volume
3.86 million shs
Market Capitalization
$17.24 billion
P/E Ratio
6.51
Dividend Yield
3.43%
Price Target
$45.18

Baxter International MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
33.3% Upside
$45.18 Price Target
Short Interest
Healthy
1.56% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.31mentions of Baxter International in the last 14 days
Based on 21 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
9.62%
From $2.91 to $3.19 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.93 out of 5 stars

Medical Sector

43rd out of 931 stocks

Surgical & Medical Instruments Industry

10th out of 101 stocks

BAX stock logo

About Baxter International Stock (NYSE:BAX)

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

BAX Stock Price History

BAX Stock News Headlines

Baxter declares $0.29 dividend
Baxter Declares Quarterly Dividend
See More Headlines
Receive BAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Baxter International and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 4/1 Dividend
2/29/2024
Dividend Payable
4/01/2024
Last Earnings
5/02/2024
Today
5/28/2024
Ex-Dividend for 7/1 Dividend
5/31/2024
Dividend Payable
7/01/2024
Next Earnings (Estimated)
7/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
07181310
Employees
60,000
Year Founded
1931

Price Target and Rating

Average Stock Price Target
$45.18
High Stock Price Target
$56.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+33.5%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
10 Analysts

Profitability

Net Income
$2.66 billion
Pretax Margin
-0.01%

Debt

Sales & Book Value

Annual Sales
$14.81 billion
Cash Flow
$5.23 per share
Book Value
$16.69 per share

Miscellaneous

Free Float
508,459,000
Market Cap
$17.24 billion
Optionable
Optionable
Beta
0.64

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Jose E. Almeida (Age 62)
    Chairman of the Board, President & CEO
    Comp: $3.62M
  • Mr. Joel T. Grade (Age 53)
    Executive VP & CFO
    Comp: $829.82k
  • Ms. Heather Knight (Age 52)
    Executive VP & Group President of Medical Products and Therapies
    Comp: $1.63M
  • Mr. Alok Sonig B.E. (Age 52)
    Mba, Executive VP & Group President of Pharmaceuticals
    Comp: $1.56M
  • Mr. Christopher A. Toth (Age 44)
    Executive VP & Group President of Kidney Care
    Comp: $5.26M
  • Ms. Tobi Karchmer M.D.
    M.S., Senior VP and Chief Medical & Scientific Officer
  • Ms. Clare Trachtman
    Vice President of Investor Relations
  • Mr. David S. Rosenbloom (Age 64)
    Executive VP & General Counsel
    Comp: $776.51k
  • Ms. Stacey Eisen
    ?Senior Vice President, Chief Communications Officer & Corporate Marketing?
  • Ms. Jeanne K. Mason Ph.D.Ms. Jeanne K. Mason Ph.D. (Age 68)
    ?Executive VP & Chief Human Resources Officer
    Comp: $1.99M

BAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Baxter International stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last twelve months. There are currently 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BAX, but not buy additional shares or sell existing shares.
View BAX analyst ratings
or view top-rated stocks.

What is Baxter International's stock price target for 2024?

10 brokers have issued 1-year price objectives for Baxter International's stock. Their BAX share price targets range from $36.00 to $56.00. On average, they predict the company's stock price to reach $45.18 in the next twelve months. This suggests a possible upside of 33.3% from the stock's current price.
View analysts price targets for BAX
or view top-rated stocks among Wall Street analysts.

How have BAX shares performed in 2024?

Baxter International's stock was trading at $38.66 at the beginning of the year. Since then, BAX shares have decreased by 12.3% and is now trading at $33.90.
View the best growth stocks for 2024 here
.

Are investors shorting Baxter International?

Baxter International saw a drop in short interest in May. As of May 15th, there was short interest totaling 7,970,000 shares, a drop of 20.5% from the April 30th total of 10,020,000 shares. Based on an average daily volume of 3,830,000 shares, the days-to-cover ratio is currently 2.1 days.
View Baxter International's Short Interest
.

When is Baxter International's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our BAX earnings forecast
.

How were Baxter International's earnings last quarter?

Baxter International Inc. (NYSE:BAX) released its earnings results on Thursday, May, 2nd. The medical instruments supplier reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.04. The medical instruments supplier earned $3.59 billion during the quarter, compared to analyst estimates of $3.55 billion. Baxter International had a trailing twelve-month return on equity of 18.47% and a net margin of 17.79%. Baxter International's revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.59 EPS.
Read the conference call transcript
.

How often does Baxter International pay dividends? What is the dividend yield for Baxter International?

Baxter International announced a quarterly dividend on Tuesday, May 7th. Stockholders of record on Friday, May 31st will be paid a dividend of $0.29 per share on Monday, July 1st. This represents a $1.16 dividend on an annualized basis and a dividend yield of 3.42%. The ex-dividend date of this dividend is Friday, May 31st.
Read our dividend analysis for BAX
.

Is Baxter International a good dividend stock?

Baxter International (NYSE:BAX) pays an annual dividend of $1.16 per share and currently has a dividend yield of 3.42%. The company has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 22.31%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BAX will have a dividend payout ratio of 36.36% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BAX.

What guidance has Baxter International issued on next quarter's earnings?

Baxter International issued an update on its second quarter 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of 0.650-0.670 for the period, compared to the consensus estimate of 0.670. The company issued revenue guidance of $3.7 billion-$3.7 billion, compared to the consensus revenue estimate of $3.8 billion.

What is José (Joe) Almeida's approval rating as Baxter International's CEO?

506 employees have rated Baxter International Chief Executive Officer José (Joe) Almeida on Glassdoor.com. José (Joe) Almeida has an approval rating of 85% among the company's employees.

What other stocks do shareholders of Baxter International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include Xtrackers California Municipal Bond ETF (CA), Johnson & Johnson (JNJ), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC), Abbott Laboratories (ABT), Procter & Gamble (PG), AT&T (T) and Verizon Communications (VZ).

Who are Baxter International's major shareholders?

Baxter International's stock is owned by many different retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (0.77%), Russell Investments Group Ltd. (0.24%), Sumitomo Mitsui Trust Holdings Inc. (0.23%), Pensioenfonds Rail & OV (0.17%), California State Teachers Retirement System (0.15%) and Cincinnati Insurance Co. (0.14%). Insiders that own company stock include Albert P L Stroucken, Brian Stevens, Jacqueline Kunzler and Jeanne K Mason.
View institutional ownership trends
.

How do I buy shares of Baxter International?

Shares of BAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Baxter International have any subsidiaries?
The following companies are subsidiares of Baxter International: ApaTech Limited, Baxter (China) Investment Co. Ltd, Baxter (Hellas) EPE, Baxter (India) Private Limited, Baxter AO, Baxter Belgium SPRL, Baxter Company Ltd, Baxter Corporation (Canada), Baxter Corporation Englewood, Baxter Deutschland GmbH, Baxter Distribution Center Europe SA, Baxter Healthcare (Guangzhou) Company Ltd, Baxter Healthcare (Shanghai) Company Ltd., Baxter Healthcare (Suzhou) Company Ltd, Baxter Healthcare (Thailand) Company Limited, Baxter Healthcare (Tianjin) Co. Ltd., Baxter Healthcare Corporation, Baxter Healthcare Limited, Baxter Healthcare Limited (Hong Kong China), Baxter Healthcare Limited (Taiwan), Baxter Healthcare Pty Ltd, Baxter Healthcare SA, Baxter Healthcare SA (Singapore Woodlands Branch), Baxter Healthcare Trading (Shanghai) Co. Ltd., Baxter Holding B.V., Baxter Hospitalar Ltda., Baxter Incorporated, Baxter Innovations & Business Solutions Private Limited (India), Baxter Limited, Baxter Manufacturing (Thailand) Co. Ltd., Baxter Medical AB, Baxter Oncology GmbH, Baxter Pharmaceutical Solutions LLC, Baxter Pharmaceuticals (Asia) Pte Ltd., Baxter Pharmaceuticals India Pvt Ltd., Baxter Polska Sp. z o.o., Baxter Productos Medicos Ltda., Baxter R and D Europe SPRL, Baxter S.A. de C.V., Baxter S.A.S., Baxter S.L., Baxter S.p.A., Baxter SA, Baxter Sales and Distribution LLC, Baxter Services Europe SA, Baxter Shared Services & Competencies Limited, Baxter de Guatemala Sociedad Anonima, Bieffe Medital S.p.A., Cheetah Medical, Cheetah Medical (Israel) Ltd., Cheetah Medical (UK) Limited, Cheetah Medical Inc., Gambro AB, Gambro Dasco S.p.A., Gambro Dialysatoren GmbH, Gambro Industries SAS, Gambro Lundia AB, Gambro Renal Products Inc., Laboratorios Baxter S.A., RTS Colombia SAS, Synovis Life Technologies Inc., and Synovis Micro Companies Alliance Inc..
Read More
This page (NYSE:BAX) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners